転移性HR+/HER2乳がんの世界市場レポート 2025年

転移性HR+/HER2乳がんの市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR9.9%で159億4,000万米ドルに成長します。予測期間の成長は、新規治療法の採用増加、免疫療法の利用拡大、新興市場への進出、患者擁護・支援プログラム、QOL向上への注力などに起因すると考えられます。この期間に予想される主な動向には、次世代シーケンシング（NGS）、リキッドバイオプシー技術、バイオマーカー探索、細胞・遺伝子治療、モノクローナル抗体（mAbs）開発などの発展が含まれます。

ホルモン補充療法（HRT）の需要の高まりは、今後数年間の転移性HR+/HER2乳がん市場の拡大を牽引すると予想されます。HRTは、体内のホルモン濃度が低下した場合に、ホルモンを補充するために用いられる治療法であり、一般的には閉経期やホルモン欠乏時に用いられます。HRTの利用が増加しているのは、治療結果の改善に有効であること、従来の治療法に比べて副作用が少ないこと、精密医療が進んでいることなどが背景にあります。HRTは、内分泌療法の効果に影響を与えることなく、ほてりや膣の乾燥など、更年期のエストロゲン欠乏に伴う症状を緩和し、転移性HR+/HER2乳がん患者を支援することができます。HRTは主にがん細胞よりもホルモンバランスの乱れに対処するため、がん治療を受けている患者の生活の質を向上させる。例えば、2023年10月、NHSイングランドは、2022-23年にイングランドで1,100万件のHRT処方箋が発行され、2021-22年に比べて47%増加したと報告しました。その結果、HRTの使用拡大が転移性HR+/HER2乳がん市場の成長に寄与しています。

転移性HR+/HER2乳がん市場で事業を展開する主な企業は、治療の選択肢、市場リーチ、適応症を拡大するために併用療法を開発しています。併用療法には、化学療法、標的療法、免疫療法、ホルモン療法、その他のアプローチなど、2種類以上の治療薬を同時に使用することが含まれます。この戦略は、異なる経路を標的とすることで病状をより効果的に治療し、全体的な治療効果を高め、がんのような単一の治療に対する耐性の可能性を減らすことを目的としています。例えば、2023年7月、米国の製薬会社メルク社は、抗PD-1療法であるKEYTRUDA（ペムブロリズマブ）をFDA承認の化学療法と併用した第3相KEYNOTE-756試験を発表しました。同試験は、高リスクの早期ER+/HER2乳がん患者において病理学的完全奏効（pCR）率を有意に改善し、主要評価項目を達成しました。KEYNOTE-756は、この患者集団のネオアジュバント療法において、免疫療法レジメンを用いてpCR率の統計学的に有意な改善を示した初めての第3相試験です。この試験では、高リスクの早期ER+/HER2-乳がんを対象に、KEYTRUDAと化学療法を併用したネオアジュバント療法を行い、その後KEYTRUDAと内分泌療法を併用したアジュバント療法を行いました。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界転移性HR+/HER2乳がんPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の転移性HR+/HER2乳がん市場：成長率分析
• 世界の転移性HR+/HER2乳がん市場の実績：規模と成長, 2019-2024
• 世界の転移性HR+/HER2乳がん市場の予測：規模と成長, 2024-2029, 2034F
• 世界転移性HR+/HER2乳がん総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の転移性HR+/HER2乳がん市場薬物によって、実績と予測, 2019-2024, 2024-2029F, 2034F
• パクリタキセル
• タモキシフェン
• ビンブラスチン
• ラロキシフェン
• ドセタキセル
• その他の薬物
• 世界の転移性HR+/HER2乳がん市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 放射線治療
• ビタミン療法
• マクロビオティックダイエット
• ホメオパシー
• ハーブ薬
• 世界の転移性HR+/HER2乳がん市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• その他のエンドユーザー
• 世界の転移性HR+/HER2乳がん市場パクリタキセルの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ジェネリックパクリタキセル
• タキソール
• 世界の転移性HR+/HER2乳がん市場タモキシフェンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ジェネリックタモキシフェン
• ノルバデックス
• 世界の転移性HR+/HER2乳がん市場ビンブラスチンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ジェネリックビンブラスチン
• ベルバン
• 世界の転移性HR+/HER2乳がん市場ラロキシフェンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ジェネリックラロキシフェン
• エビスタ
• 世界の転移性HR+/HER2乳がん市場ドセタキセルの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ジェネリックドセタキセル
• タキソテール
• 世界の転移性HR+/HER2乳がん市場その他の医薬品の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• レトロゾール
• アナストロゾール
• エキセメスタン
• パルボシクリブ
• リボシクリブ
• アベマシクリブ

第7章 地域別・国別分析

• 世界の転移性HR+/HER2乳がん市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の転移性HR+/HER2乳がん市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 転移性HR+/HER2乳がん市場：競合情勢
• 転移性HR+/HER2乳がん市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis AG
• GlaxoSmithKline plc
• Eli Lilly and Company
• Gilead Sciences Inc.
• Amgen Inc.
• Daiichi Sankyo Company Limited
• Jiangsu Hengrui Medicine Co Ltd.
• MacroGenics Inc.
• Arvinas Inc.
• Olema Pharmaceuticals Inc.
• CytomX Therapeutics Inc.
• G1 Therapeutics Inc.
• Context Therapeutics Inc.
• Celcuity Inc.
• Sermonix Pharmaceuticals Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 転移性HR+/HER2乳がん市場2029：新たな機会を提供する国
• 転移性HR+/HER2乳がん市場2029：新たな機会を提供するセグメント
• 転移性HR+/HER2乳がん市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Metastatic HR+/HER2- breast cancer is a form of breast cancer where the cancer cells have spread from the breast to other parts of the body. Treatment typically involves targeted therapies, hormonal treatments, and chemotherapy to manage disease progression and enhance patient outcomes.

The primary drugs used for metastatic HR+/HER2- breast cancer include paclitaxel, tamoxifen, vinblastine, raloxifene, docetaxel, and other medications. Paclitaxel is a chemotherapy drug that works by stabilizing microtubules, preventing cancer cells from dividing and growing. These treatments are often combined with other approaches such as radiation therapy, vitamin therapy, macrobiotic diets, homeopathy, and herbal medicine. They are used in various healthcare settings, including hospitals, clinics, and other medical facilities.

The metastatic HR+/HER2- breast cancer market research report is one of a series of new reports from The Business Research Company that provides metastatic HR+/HER2- breast cancer market statistics, including metastatic HR+/HER2- breast cancer industry global market size, regional shares, competitors with a metastatic HR+/HER2- breast cancer market share, detailed metastatic HR+/HER2- breast cancer market segments, market trends and opportunities, and any further data you may need to thrive in the metastatic HR+/HER2- breast cancer industry. This metastatic HR+/HER2- breast cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The metastatic HR+/HER2-breast cancer market size has grown rapidly in recent years. It will grow from $9.91 billion in 2024 to $10.92 billion in 2025 at a compound annual growth rate (CAGR) of 10.3%. The growth during the historic period can be attributed to increased awareness about early diagnosis, higher diagnosis rates, successes in clinical trials, pharmaceutical investments, and the growing adoption of combination therapies.

The metastatic HR+/HER2-breast cancer market size is expected to see strong growth in the next few years. It will grow to $15.94 billion in 2029 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to the increasing adoption of novel therapies, a growing use of immunotherapy, expansion into emerging markets, patient advocacy and support programs, and a focus on improving quality of life. Key trends expected during this period include advancements in next-generation sequencing (NGS), liquid biopsy technologies, biomarker discovery, cell and gene therapies, and the development of monoclonal antibodies (mAbs).

The growing demand for hormone replacement therapy (HRT) is anticipated to drive the expansion of the metastatic HR+/HER2- breast cancer market in the coming years. HRT is a medical treatment used to replace or supplement hormones that are at lower levels in the body, commonly during menopause or when hormone deficiencies occur. The rising use of HRT is attributed to its effectiveness in improving treatment outcomes, fewer side effects compared to traditional therapies, and advances in precision medicine. HRT can assist metastatic HR+/HER2- breast cancer patients by relieving symptoms associated with estrogen deficiency during menopause, such as hot flashes and vaginal dryness, without affecting the efficacy of endocrine therapies. Since HRT primarily addresses hormone imbalances rather than cancerous cells, it ensures better quality of life for patients undergoing cancer treatment. For example, in October 2023, NHS England reported that 11 million HRT prescriptions were issued in England during 2022-23, a 47% increase compared to 2021-22. Consequently, the growing use of HRT is contributing to the growth of the metastatic HR+/HER2- breast cancer market.

Key companies operating in the metastatic HR+/HER2- breast cancer market are developing combination therapies to expand treatment options, market reach, and indications. Combination therapy involves using two or more therapeutic agents simultaneously, such as chemotherapy, targeted therapy, immunotherapy, hormone therapy, or other approaches. This strategy is designed to treat medical conditions more effectively by targeting different pathways, enhancing overall treatment response, and reducing the chance of resistance to a single treatment, such as cancer. For example, in July 2023, Merck & Co., Inc., a US-based pharmaceutical company, announced the Phase 3 KEYNOTE-756 trial, which evaluated KEYTRUDA (pembrolizumab), an anti-PD-1 therapy, combined with FDA-approved chemotherapy. The trial met its primary endpoint by significantly improving the pathological complete response (pCR) rate in patients with high-risk, early-stage ER+/HER2- breast cancer. KEYNOTE-756 is the first Phase 3 trial to show a statistically significant improvement in pCR rates using an immunotherapy regimen in the neoadjuvant setting for this patient population. The trial tested KEYTRUDA with chemotherapy as neoadjuvant treatment, followed by adjuvant KEYTRUDA plus endocrine therapy for high-risk, early-stage ER+/HER2- breast cancer.

In November 2023, Carrum Health, a US-based healthcare solutions provider, entered into a partnership with Texas Oncology to enhance affordable breast cancer care. Through this collaboration, Carrum Health plans to offer a bundled package for breast cancer treatment, including two years of coverage for chemotherapy, radiation, and symptom management from Texas Oncology. This partnership aims to provide high-quality, cost-effective care. Texas Oncology, a US-based provider, specializes in treating metastatic HR+/HER2- breast cancer.

Major players in the metastatic hr+/her2- breast cancer market are Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Daiichi Sankyo Company Limited, Jiangsu Hengrui Medicine Co Ltd., MacroGenics Inc., Arvinas Inc., Olema Pharmaceuticals Inc., CytomX Therapeutics Inc., G1 Therapeutics Inc., Context Therapeutics Inc., Celcuity Inc., Sermonix Pharmaceuticals Inc., Ambrx Biopharma Inc., Carrick Therapeutics.

North America was the largest region in the dominated market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in metastatic HR+/HER2- breast cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the metastatic HR+/HER2- breast cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The metastatic HR+/HER2- breast cancer market consists revenues earned by entities by providing services such as endocrine therapy, and immunotherapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The metastatic HR+/HER2- breast cancer market also includes sales of CDK4/6 inhibitors, PI3K inhibitors, mTOR inhibitors, and chemotherapy agents. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Metastatic HR+/HER2- Breast Cancer Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on metastatic hr+/her2- breast cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for metastatic hr+/her2- breast cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The metastatic hr+/her2- breast cancer market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drugs: Paclitaxel; Tamoxifen; Vinblastine; Raloxifene; Docetaxel; Other Drugs
• 2) By Treatment: Radiation Therapy; Vitamin Therapy; Macrobiotic Diets; Homeopathy; Herbal Medication
• 3) By End-User: Hospitals; Clinics; Other End-User
• Subsegments:
• 1) By Paclitaxel: Generic Paclitaxel; Taxol
• 2) By Tamoxifen: Generic Tamoxifen; Nolvadex
• 3) By Vinblastine: Generic Vinblastine; Velban
• 4) By Raloxifene: Generic Raloxifene; Evista
• 5) By Docetaxel: Generic Docetaxel; Taxotere
• 6) By Other Drugs: Letrozole; Anastrozole; Exemestane; Palbociclib; Ribociclib; Abemaciclib
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Sanofi S.A.; Bristol-Myers Squibb Company; AstraZeneca PLC
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Metastatic HR+/HER2- Breast Cancer Market Characteristics

3. Metastatic HR+/HER2- Breast Cancer Market Trends And Strategies

4. Metastatic HR+/HER2- Breast Cancer Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Metastatic HR+/HER2- Breast Cancer Growth Analysis And Strategic Analysis Framework

• 5.1. Global Metastatic HR+/HER2- Breast Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Metastatic HR+/HER2- Breast Cancer Market Growth Rate Analysis
• 5.4. Global Metastatic HR+/HER2- Breast Cancer Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Metastatic HR+/HER2- Breast Cancer Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Metastatic HR+/HER2- Breast Cancer Total Addressable Market (TAM)

6. Metastatic HR+/HER2- Breast Cancer Market Segmentation

• 6.1. Global Metastatic HR+/HER2- Breast Cancer Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Paclitaxel
• Tamoxifen
• Vinblastine
• Raloxifene
• Docetaxel
• Other Drugs
• 6.2. Global Metastatic HR+/HER2- Breast Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Radiation Therapy
• Vitamin Therapy
• Macrobiotic Diets
• Homeopathy
• Herbal Medication
• 6.3. Global Metastatic HR+/HER2- Breast Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Other End-User
• 6.4. Global Metastatic HR+/HER2- Breast Cancer Market, Sub-Segmentation Of Paclitaxel, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Generic Paclitaxel
• Taxol
• 6.5. Global Metastatic HR+/HER2- Breast Cancer Market, Sub-Segmentation Of Tamoxifen, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Generic Tamoxifen
• Nolvadex
• 6.6. Global Metastatic HR+/HER2- Breast Cancer Market, Sub-Segmentation Of Vinblastine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Generic Vinblastine
• Velban
• 6.7. Global Metastatic HR+/HER2- Breast Cancer Market, Sub-Segmentation Of Raloxifene, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Generic Raloxifene
• Evista
• 6.8. Global Metastatic HR+/HER2- Breast Cancer Market, Sub-Segmentation Of Docetaxel, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Generic Docetaxel
• Taxotere
• 6.9. Global Metastatic HR+/HER2- Breast Cancer Market, Sub-Segmentation Of Other Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Letrozole
• Anastrozole
• Exemestane
• Palbociclib
• Ribociclib
• Abemaciclib

7. Metastatic HR+/HER2- Breast Cancer Market Regional And Country Analysis

• 7.1. Global Metastatic HR+/HER2- Breast Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Metastatic HR+/HER2- Breast Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Metastatic HR+/HER2- Breast Cancer Market

• 8.1. Asia-Pacific Metastatic HR+/HER2- Breast Cancer Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Metastatic HR+/HER2- Breast Cancer Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Metastatic HR+/HER2- Breast Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Metastatic HR+/HER2- Breast Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Metastatic HR+/HER2- Breast Cancer Market

• 9.1. China Metastatic HR+/HER2- Breast Cancer Market Overview
• 9.2. China Metastatic HR+/HER2- Breast Cancer Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Metastatic HR+/HER2- Breast Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Metastatic HR+/HER2- Breast Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Metastatic HR+/HER2- Breast Cancer Market

• 10.1. India Metastatic HR+/HER2- Breast Cancer Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Metastatic HR+/HER2- Breast Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Metastatic HR+/HER2- Breast Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Metastatic HR+/HER2- Breast Cancer Market

• 11.1. Japan Metastatic HR+/HER2- Breast Cancer Market Overview
• 11.2. Japan Metastatic HR+/HER2- Breast Cancer Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Metastatic HR+/HER2- Breast Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Metastatic HR+/HER2- Breast Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Metastatic HR+/HER2- Breast Cancer Market

• 12.1. Australia Metastatic HR+/HER2- Breast Cancer Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Metastatic HR+/HER2- Breast Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Metastatic HR+/HER2- Breast Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Metastatic HR+/HER2- Breast Cancer Market

• 13.1. Indonesia Metastatic HR+/HER2- Breast Cancer Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Metastatic HR+/HER2- Breast Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Metastatic HR+/HER2- Breast Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Metastatic HR+/HER2- Breast Cancer Market

• 14.1. South Korea Metastatic HR+/HER2- Breast Cancer Market Overview
• 14.2. South Korea Metastatic HR+/HER2- Breast Cancer Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Metastatic HR+/HER2- Breast Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Metastatic HR+/HER2- Breast Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Metastatic HR+/HER2- Breast Cancer Market

• 15.1. Western Europe Metastatic HR+/HER2- Breast Cancer Market Overview
• 15.2. Western Europe Metastatic HR+/HER2- Breast Cancer Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Metastatic HR+/HER2- Breast Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Metastatic HR+/HER2- Breast Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Metastatic HR+/HER2- Breast Cancer Market

• 16.1. UK Metastatic HR+/HER2- Breast Cancer Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Metastatic HR+/HER2- Breast Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Metastatic HR+/HER2- Breast Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Metastatic HR+/HER2- Breast Cancer Market

• 17.1. Germany Metastatic HR+/HER2- Breast Cancer Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Metastatic HR+/HER2- Breast Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Metastatic HR+/HER2- Breast Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Metastatic HR+/HER2- Breast Cancer Market

• 18.1. France Metastatic HR+/HER2- Breast Cancer Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Metastatic HR+/HER2- Breast Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Metastatic HR+/HER2- Breast Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Metastatic HR+/HER2- Breast Cancer Market

• 19.1. Italy Metastatic HR+/HER2- Breast Cancer Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Metastatic HR+/HER2- Breast Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Metastatic HR+/HER2- Breast Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Metastatic HR+/HER2- Breast Cancer Market

• 20.1. Spain Metastatic HR+/HER2- Breast Cancer Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Metastatic HR+/HER2- Breast Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Metastatic HR+/HER2- Breast Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Metastatic HR+/HER2- Breast Cancer Market

• 21.1. Eastern Europe Metastatic HR+/HER2- Breast Cancer Market Overview
• 21.2. Eastern Europe Metastatic HR+/HER2- Breast Cancer Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Metastatic HR+/HER2- Breast Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Metastatic HR+/HER2- Breast Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Metastatic HR+/HER2- Breast Cancer Market

• 22.1. Russia Metastatic HR+/HER2- Breast Cancer Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Metastatic HR+/HER2- Breast Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Metastatic HR+/HER2- Breast Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Metastatic HR+/HER2- Breast Cancer Market

• 23.1. North America Metastatic HR+/HER2- Breast Cancer Market Overview
• 23.2. North America Metastatic HR+/HER2- Breast Cancer Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Metastatic HR+/HER2- Breast Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Metastatic HR+/HER2- Breast Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Metastatic HR+/HER2- Breast Cancer Market

• 24.1. USA Metastatic HR+/HER2- Breast Cancer Market Overview
• 24.2. USA Metastatic HR+/HER2- Breast Cancer Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Metastatic HR+/HER2- Breast Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Metastatic HR+/HER2- Breast Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Metastatic HR+/HER2- Breast Cancer Market

• 25.1. Canada Metastatic HR+/HER2- Breast Cancer Market Overview
• 25.2. Canada Metastatic HR+/HER2- Breast Cancer Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Metastatic HR+/HER2- Breast Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Metastatic HR+/HER2- Breast Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Metastatic HR+/HER2- Breast Cancer Market

• 26.1. South America Metastatic HR+/HER2- Breast Cancer Market Overview
• 26.2. South America Metastatic HR+/HER2- Breast Cancer Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Metastatic HR+/HER2- Breast Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Metastatic HR+/HER2- Breast Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Metastatic HR+/HER2- Breast Cancer Market

• 27.1. Brazil Metastatic HR+/HER2- Breast Cancer Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Metastatic HR+/HER2- Breast Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Metastatic HR+/HER2- Breast Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Metastatic HR+/HER2- Breast Cancer Market

• 28.1. Middle East Metastatic HR+/HER2- Breast Cancer Market Overview
• 28.2. Middle East Metastatic HR+/HER2- Breast Cancer Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Metastatic HR+/HER2- Breast Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Metastatic HR+/HER2- Breast Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Metastatic HR+/HER2- Breast Cancer Market

• 29.1. Africa Metastatic HR+/HER2- Breast Cancer Market Overview
• 29.2. Africa Metastatic HR+/HER2- Breast Cancer Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Metastatic HR+/HER2- Breast Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Metastatic HR+/HER2- Breast Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Metastatic HR+/HER2- Breast Cancer Market Competitive Landscape And Company Profiles

• 30.1. Metastatic HR+/HER2- Breast Cancer Market Competitive Landscape
• 30.2. Metastatic HR+/HER2- Breast Cancer Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

31. Metastatic HR+/HER2- Breast Cancer Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. GlaxoSmithKline plc
• 31.3. Eli Lilly and Company
• 31.4. Gilead Sciences Inc.
• 31.5. Amgen Inc.
• 31.6. Daiichi Sankyo Company Limited
• 31.7. Jiangsu Hengrui Medicine Co Ltd.
• 31.8. MacroGenics Inc.
• 31.9. Arvinas Inc.
• 31.10. Olema Pharmaceuticals Inc.
• 31.11. CytomX Therapeutics Inc.
• 31.12. G1 Therapeutics Inc.
• 31.13. Context Therapeutics Inc.
• 31.14. Celcuity Inc.
• 31.15. Sermonix Pharmaceuticals Inc.

32. Global Metastatic HR+/HER2- Breast Cancer Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Metastatic HR+/HER2- Breast Cancer Market

34. Recent Developments In The Metastatic HR+/HER2- Breast Cancer Market

35. Metastatic HR+/HER2- Breast Cancer Market High Potential Countries, Segments and Strategies

• 35.1 Metastatic HR+/HER2- Breast Cancer Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Metastatic HR+/HER2- Breast Cancer Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Metastatic HR+/HER2- Breast Cancer Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer